US5622985A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
Assignee: Bristol Myers Squibb Co
•
Filing: 1995-04-19
•
Granted: 1997-04-22
•
Expires: 2015-04-19
Abstract
Abstract A method is provided for preventing or reducing the risk of a second heart attack in a patient having a substantially normal serum cholesterol level by administering an HMG CoA reductase inhibitor such as pravastatin, alone or in combination with an ACE inhibitor.
Inventors
- 👤 Adeove Y. Olukotun
- 👤 John C. Alexander
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:18
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K31/4155; A61K31/21; A61K31/215; A61K31/22; A61K31/335; A61K31/365; A61K31/366; A61K31/40; A61K31/401; A61K31/4025; A61K31/4164; A61K31/4178; A61K31/66; A61K31/662; A61K31/664; A61K38/00; A61K38/16; A61K38/55; A61K38/556; A61P; A61P3/00; A61P3/06; A61P43/00; A61P9/00
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
59 words
A method for preventing or reducing the risk of a second heart attack in a mammalian species having a substantially normal serum cholesterol level, which comprises administering to a mammalian species having a substantially normal serum cholesterol level in need of such treatment a therapeutically effective amount of an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase.
Claim 2
Independent Claim
59 words
A method for preventing or reducing the risk of a second heart attack in a mammalian species having a substantially normal serum cholesterol level, which comprises administering to a mammalian species having a substantially normal serum cholesterol level in need of such treatment a therapeutically effective amount of an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase.
Claim 3
Dependent Claim
22 words
The method as defined in claim 1 wherein said inhibitor of the enzyme HMG CoA reductase is mevastatin, lovastatin, pravastatin or velostatin.
Claim 4
Dependent Claim
59 words
The method as defined in claim 1 wherein said inhibitor of the enzyme HMG CoA reductase is a pyrazole analog of a mevalonolactone, an indene analog of mevalonolactone, a 3-carboxy-2-hydroxypropane-phosphinic acid derivative, a 6-[2-(substituted-pyrrol-1-yl)-alkyl]pyran-2-one, an imidazole analog of mevalonolactone, a naphthyl analog of mevalonolactone, an octahydro-naphthalene, fluindostatin, a keto analog of lovastatin or a 2,3-di-substituted pyrrole, furan or thiophene.
Claim 5
Dependent Claim
15 words
The method as defined in claim 1 wherein said HMG CoA reductase inhibitor is pravastatin.
Claim 6
Dependent Claim
32 words
The method as defined in claim 1 wherein said HMG CoA reductase inhibitor is administered in single or divided doses of from about 0.5 to about 100 mg/one to four times daily.
Claim 7
Dependent Claim
32 words
The method as defined in claim 1 wherein said HMG CoA reductase inhibitor is administered in single or divided doses of from about 5 to about 80 mg/one to four times daily.
Claim 8
Independent Claim
67 words
A method for preventing or reducing the risk of a second heart attack in a mammalian species having a substantially normal serum cholesterol level, which comprises administering to a mammalian species having a substantially normal serum cholesterol level in need of such treatment a therapeutically effective amount of an HMG CoA reductase inhibitor in combination with a therapeutically effective amount of an angiotensin converting enzyme (ACE) inhibitor.
Claim 9
Independent Claim
67 words
A method for preventing or reducing the risk of a second heart attack in a mammalian species having a substantially normal serum cholesterol level, which comprises administering to a mammalian species having a substantially normal serum cholesterol level in need of such treatment a therapeutically effective amount of an HMG CoA reductase inhibitor in combination with a therapeutically effective amount of an angiotensin converting enzyme (ACE) inhibitor.
Claim 10
Dependent Claim
17 words
The method as defined in claim 7 wherein the angiotensin converting enzyme inhibitor is captopril or fosinopril.
Claim 11
Dependent Claim
23 words
The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor includes a mercapto moiety and is a substituted proline derivative.
Claim 12
Dependent Claim
22 words
The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor is captopril, zofenopril, enalapril, ceranopril, fosinopril, lisinopril or fentiapril.
Claim 13
Dependent Claim
40 words
The method as defined in claim 7 wherein the angiotensin converting enzyme inhibitor is a phosphonate substituted amino or imino acid or salt thereof, a mercaptoacyl derivative of a substituted proline, a carboxyalkyl dipeptide, a phosphinylalkanoyl proline or a phosphonoamidate.
Claim 14
Dependent Claim
34 words
The method as defined in claim 7 wherein the HMG CoA reductase inhibitor is present in a weight ratio to the ACE inhibitor of within the range of from about 0.001:1 to about 1000:1.
Claim 15
Dependent Claim
15 words
The method as defined in claim 7 wherein the HMG CoA reductase inhibitor is pravastatin.
Claim 16
Dependent Claim
32 words
The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor is administered in single or divided doses of from about 0.1 to about 500 mg/one to four times daily.
Claim 17
Dependent Claim
24 words
The method as defined in claim 7 wherein the HMG CoA reductase inhibitor is pravastatin and the ACE inhibitor is captopril, fosinopril or ceranopril.
Claim 18
Dependent Claim
32 words
The method as defined in claim 7 wherein said angiotensin converting enzyme inhibitor is administered in single or divided doses of from about 2 to about 50 mg/one to four times daily.
Claim 19
Dependent Claim
14 words
The method as defined in claim 7 wherein the mammalian species treated is normotensive.
Claim 20
Dependent Claim
23 words
The method as defined in claim 17 wherein the ACE inhibitor is administered in an amount below that required to cause hemodynamic effects.
Claim 21
Dependent Claim
50 words
The method as defined in claim 7 wherein the HMG CoA reductase inhibitor is employed in an amount of within the range of from about 5 to about 80 mg and the ACE inhibitor is employed in an amount within the range of from about 2 to about 5 mg.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-04-21 | 2000-10-21 | 2001-04-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-04-21 | 2004-10-21 | 2005-04-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-04-21 | 2008-10-21 | 2009-04-22 | $7700.00 | Window Closed / Lapsed |